Phase
Condition
Brain Cancer
Gliomas
Astrocytoma
Treatment
D2C7-IT
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients must have a recurrent supratentorial WHO grade III or IV malignant gliomabased on imaging studies;
Prior histopathology consistent with a supratentorial WHO grade III or IV malignantglioma;
Following biopsy, prior to administration of D2C7-IT, the presence of recurrenttumor must be confirmed by histopathological analysis;
Age ≥ 18 years of age;
Karnofsky Performance Status (KPS) ≥ 70%;
Laboratory Values:
Platelet count ≥ 100,000/µl unsupported is necessary for eligibility on thestudy; however, because of risks of intracranial hemorrhage with catheterplacement, platelet count ≥ 125,000/µl is required for the patient to undergobiopsy and catheter insertion, which can be attained with the help of platelettransfusion;
Hemoglobin ≥ 9 gm/dL prior to biopsy;
Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 prior to biopsy;
Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) prior to biopsy;
Liver Function: Total bilirubin ≤ 1.5 x ULN prior to biopsy (Exception: Patienthas known Gilbert's Syndrome or patient has suspected Gilbert's Syndrome, forwhich additional lab testing of direct and/or indirect bilirubin supports thisdiagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN isacceptable.); AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 2.5 x the ULN prior to biopsy;
Prothrombin (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x upperlimit of normal (ULN) prior to biopsy. Patients with prior history ofthrombosis/embolism are allowed to be on anticoagulation, understanding thatanti-coagulation will be held in the peri-operative period per theneurosurgical team's recommendations. Low molecular weight heparin (LMWH) ispreferred. If a patient is on warfarin, the international normalized ratio (INR) is to be obtained and value should be below 2.0 prior to biopsy;
Ability to comply with study and follow-up procedures;
If the patient is a sexually active female of child bearing potential, whosepartner is male, or if the patient is a sexually active male, whose partner isa female of child bearing potential, the patient must agree to use appropriatecontraceptive measures for the duration of the treatment of the tumor and for 6months afterwards as stated in the informed consent. Female patients of childbearing potential must have a negative serum pregnancy test at the time ofscreening and within 48 hours of starting the D2C7-IT infusion
Patients will sign an IRB-approved informed consent form prior to any study-relatedprocedures.
Able to undergo brain MRI with and without contrast.
Exclusion
Exclusion Criteria:
Prior, unrelated malignancy requiring current active treatment with the exception ofcervical carcinoma in situ and adequately treated basal cell or squamous cellcarcinoma of the skin;
Pregnant or breastfeeding;
Patients with contrast-enhancing tumor component crossing the midline, activelygrowing multi-focal tumor, infratentorial tumor or extensive tumor dissemination (subependymal or leptomeningeal);
Patients with clinically significant increased intracranial pressure (e.g.,impending herniation), uncontrolled seizures, or requirement for immediatepalliative treatment;
Patients with a known severe allergy to Gadolinium-DTPA. Patients with mildallergies (e.g., rash only) will be pretreated with acetaminophen anddiphenhydramine prior to injection of the contrast agent;
Unstable systemic disease in the opinion of the treating physician, for exampleactive infection requiring IV antibiotics;
Patients on greater than 4mg per day of dexamethasone within the 2 weeks prior toadmission for D2C7-IT infusion;
Patients with worsening steroid myopathy (history of gradual progression ofbilateral proximal muscle weakness, and atrophy of proximal muscle groups);
Patients who have not completed standard of care treatment prior to participation inthis trial, i.e. surgical procedure and radiation therapy (at least 59 Gy). Note: Iftumor is unmethylated, patients are not mandated to have received chemotherapy priorto participation in this trial. However, if tumor is methylated, patients must havereceived at least one chemotherapy regimen prior to participation in this trial.
Less than 12 weeks from radiation therapy, unless progressive disease outside of theradiation field or 2 progressive scans at least 4 weeks apart or histopathologicconfirmation;
Treated with immunotherapeutic agents within 4 weeks before enrollment, unless thepatient has recovered from the expected toxic effects of such therapy;
Treated with antiangiogenic agents (like bevacizumab) within 4 weeks before biopsy;
Treated with alkylating agents within 4 weeks before enrollment (6 weeks fornitrosoureas) or treated within 1 week before enrollment with daily or metronomicchemotherapy, unless the patient has recovered from the expected toxic effects ofsuch therapy;
Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unlessthe patient has recovered from the expected toxic effects of such therapy.
Study Design
Study Description
Connect with a study center
Preston Robert Tisch Brain Tumor Center at Duke
Durham, North Carolina 27710
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.